Clinical Trials
30
Active:3
Completed:9
Trial Phases
4 Phases
Phase 1:21
Phase 2:6
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Phase 1
21 (70.0%)Phase 2
6 (20.0%)Not Applicable
2 (6.7%)Phase 3
1 (3.3%)A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: ABSK043 in combination with Glecirasib
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT07164170
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing Municipality, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 38
- Registration Number
- NCT07126249
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT07007546
- Locations
- 🇨🇳
Jiangnan University Affiliated Hospital, Wuxi, Jiangsu, China
A Mass Balance Study of [14C]ABSK011
Phase 1
Not yet recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: [14C]ABSK011
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT06896760
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: Pimicotinib capsule
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06884072
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found